Navigation Links
Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 June 2008
Date:8/19/2008

.S. health authorities for evaluation of whether the data can support the use of IMVAMUNE(R) in a declared emergency. The completed submission will trigger a milestone payment of USD 25 million under the RFP-3 contract, which is expected in the fourth quarter of 2008.

An end of Phase II meeting request is expected to be submitted to the FDA in the second half of 2008 in order to discuss the Phase III study design and data requirements for a biologic licence application (BLA) with the FDA. Subsequently, the clinical activities to support Phase III studies are still expected to start in 2009.

The first deliveries of vaccines are expected in 2009. With a view to optimising the use of resources at the manufacturing facility at Kvistgard, Denmark, delivery of vaccines is expected to be distributed over the period 2009-2011. At the manufacturing facility, routine production has now been demonstrated over a period of a full year and Bavarian Nordic is currently in the first phase of increasing output.

Update on commercial activities

In first half of 2008, Bavarian Nordic signed contract with an Asian country for the delivery of a small order of IMVAMUNE(R). This initial order was the first since the award of the US contract for 20 million doses of IMVAMUNE(R) in 2007. The extent and value of the contract are undisclosed. Bavarian Nordic will manufacture and deliver IMVAMUNE(R) smallpox vaccines for this country before initiating the delivery of the 20 million doses of IMVAMUNE(R) for the U.S. government.

The commercial activities in Asia as well as in Europe and the Middle East have been expanded during the past six months and both Bavarian Nordic staff, as well as local agents experienced in government contracting are operating in teams in these three areas. Furthermore, Bavarian Nordic has engaged highly experienced people with knowledge within bio-terror and bio-preparedness to support the teams, enabling them to enter a professional a
'/>"/>

SOURCE Bavarian Nordic A/S
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Bavarian Nordic Update - 2007 Annual Results, IMVAMUNE(R) Delivery Contract, Strategy Process
2. Bavarian Nordic Receives $50 Million Advance Payment from HHS for Fulfilling Contract Milestones
3. LPBP Inc. - Re-filing certification of interim filings
4. Fufeng Announces 2008 Interim Results With Strong Sign of Recovery
5. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
6. Chromos obtains interim order in connection with arrangement, announces annual and special meeting of shareholders and confirms mailing of information circular
7. Quest PharmaTech Announces Interim Results from Phase I/II Clinical Trial for Photodynamic Treatment for Hair Removal
8. Angiotechs corporate partner, Cook Medical, announces positive interim results for its Zilver(R) PTX(TM) clinical study
9. Clarification on Press Release Issued Earlier Today: Targeted Genetics Confirms Positive, Interim Phase 1/2 Study Findings
10. Steve Davis Joins Infectious Disease Research Institute (IDRI) as Interim CEO
11. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Combination REOLYSIN(R) and Carboplatin/Paclitaxel Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)SAN FRANCISCO, Dec. 3 VIA Pharmaceuticals, Inc. (Nasdaq: VIAP ), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today anno
(Date:12/3/2009)TUSTIN, Calif., Dec. 3 Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) today announced that it will release its financial results for the second quarter of fiscal year 2010 on December 10, 2009 at 7
(Date:12/3/2009)HOPKINTON, Mass., Dec. 3 Caliper Life Sciences, Inc. (Nasdaq: CALP ), a leading provider of tools and services for drug discovery and life sciences research, today introduced Living Image 4.0 softwa
(Date:12/2/2009)COLUMBIA, Md., Dec. 2 Martek Biosciences Corporation (Nasdaq: MATK ) announced today that it intends to release the results of its fourth quarter and fiscal year 2009 on December 16, 2009, at approx
Breaking Biology Technology:VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 2VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 3VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 4Peregrine Pharmaceuticals to Report Second Quarter FY 2010 Financial Results 2Caliper Life Sciences Launches Living Image(R) 4.0 Software 2Martek to Announce Fourth Quarter and Fiscal Year 2009 Results 2
(Date:12/3/2009)WALL, N.J., Dec. 3 BIO-key International, Inc. (OTC Bulletin Board: BKYI), a leader in wireless public safety and finger-based biometric identification solutions, announced that a majority of its sha
(Date:12/3/2009)Contents of this message: , , Preliminary Press Conference Topics, Last Call! Press Field Trip to California Academy of Sciences museum, Attention PIOs: Sending Press Releases to Fall meeting, N
(Date:12/3/2009)Have you ever felt overly upset by a social snubbing? Your genetics, not your friends, may be at fault. , Scientists have long known that opium-like painkillers, called opioids, relieve not only phys
Breaking Biology News(10 mins):BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 2BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 3AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 2AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 3AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 4AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 5AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 6Weekend Weather Prompts Air Quality Advisories 54577 1Weekend Weather Prompts Air Quality Advisories 54577 2Weekend Weather Prompts Air Quality Advisories 54577 3The Dannon Company Awards Cornell Cooperative Extension of Westchester County the Fourth Annual Dannon Next Generation Nutrition Grant 54575 1The Dannon Company Awards Cornell Cooperative Extension of Westchester County the Fourth Annual Dannon Next Generation Nutrition Grant 54575 2The Dannon Company Awards Cornell Cooperative Extension of Westchester County the Fourth Annual Dannon Next Generation Nutrition Grant 54575 3The Dannon Company Awards Cornell Cooperative Extension of Westchester County the Fourth Annual Dannon Next Generation Nutrition Grant 54575 4The Dannon Company Awards Cornell Cooperative Extension of Westchester County the Fourth Annual Dannon Next Generation Nutrition Grant 54575 5Senetek PLC Reports Second Quarter 2009 Financial Results 54573 1Senetek PLC Reports Second Quarter 2009 Financial Results 54573 2Senetek PLC Reports Second Quarter 2009 Financial Results 54573 3Senetek PLC Reports Second Quarter 2009 Financial Results 54573 4Senetek PLC Reports Second Quarter 2009 Financial Results 54573 5Senetek PLC Reports Second Quarter 2009 Financial Results 54573 6
...itor Assay Kits are ideal for studying or screenin...ing fluorescence polarization (FP) The homogenous ... to the ligand binding domain of human progesteron...scently-tagged progesterone ligand, Fluormone PL G...
...ifically to Fc regions of many mammalian immunoglo...monly used as affinity adsorbents to purify immuno... from serum, hybridoma ascites fluids, tissue cult...e reagents are also commonly used to capture immun...
...rument engineered to match the speed of biochemica...enters worldwide. It uses 1.5 mm Roche LightCycler...-speed temperature cycling due to their thin walls...,By combining glass capillary tubes and air as th...
Freund's Incomplete Adjuvant, Modified from Calbiochem
Biology Products: